drugset / Trial / NCT02946047

The Effect of Ixazomib on the Latent HIV Reservoir

NCT02946047

Phase 1/2 Completed 17 enrolled Mayo Clinic Takeda · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

The primary purpose of the trial is to determine the safety and tolerability of ixazomib in HIV infected patients on antiretroviral therapy. The secondary purpose is to determine the effect of ixazomib on the size of the HIV reservoir.

Timeline

Start
2017-03-20
Primary completion
2019-08-19
Completion
2019-08-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixazomib Unknown 1 mg
Subject Ixazomib Unknown 2 mg
Subject Ixazomib Unknown 3 mg
Subject Ixazomib Unknown 4 mg